NeuroOne Medical Technologies Corporation (NMTC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NeuroOne Medical Technologies Corporation (NMTC) Healthcare & Pipeline Overview

NeuroOne Medical Technologies Corporation, a medical device company, specializes in thin film electrode technology for treating neurological disorders. Their focus on cEEG, sEEG, spinal cord stimulation, brain stimulation, and ablation solutions, coupled with a partnership with RBC Medical Innovations, positions them in the neuromodulation market.

What Is the Investment Thesis for NMTC?

NeuroOne Medical Technologies Corporation presents a speculative investment opportunity within the neuromodulation market. The company's focus on thin film electrode technology for various neurological applications, including epilepsy and Parkinson's disease, positions it in a high-growth area. A key value driver is the strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. Upcoming catalysts include regulatory milestones for its sEEG and ablation products. However, potential risks include the company's small market capitalization of $13.8M, negative profit margin of -78.3%, and the challenges inherent in bringing novel medical devices to market. Successful commercialization and regulatory approvals are critical for realizing the company's potential.

Based on FMP financials and quantitative analysis

NMTC Key Highlights

Market capitalization of $13.8M indicates a small-cap company with potential for high growth but also higher risk.

• Gross margin of 54.9% suggests strong pricing power for its products, but needs to be balanced against high operating expenses.
• Profit margin of -78.3% reflects significant ongoing investments in R&D and commercialization efforts.
• Beta of 0.58 indicates lower volatility compared to the overall market.
• Strategic partnership with RBC Medical Innovations provides access to complementary technologies and expertise.

Who Are NMTC's Competitors?

NMTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NMTC's Key Strengths?

Proprietary thin film electrode technology.

• Strategic partnership with RBC Medical Innovations.
• Focus on high-growth neuromodulation market.
• Potential for disruptive innovation in electrode technology.

What Are NMTC's Weaknesses?

Small market capitalization and limited financial resources.

• Negative profit margin and reliance on external funding.
• Dependence on regulatory approvals for product commercialization.
• Limited commercial track record.

What Could Drive NMTC Stock Higher?

FDA clearance for sEEG electrode technology.

• Completion of development for radio frequency ablation generator with RBC Medical Innovations.
• Expansion of clinical studies to demonstrate the efficacy of NeuroOne's technology.
• Pursuit of strategic partnerships for expanded market access.

What Are the Key Risks for NMTC?

Financial-distress signal — its Altman Z-Score of -17.00 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-98.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Delays in regulatory approvals for key products.
• Competition from established players in the neuromodulation market.
• Dependence on external funding to support operations and R&D.
• Technological obsolescence of existing products.
• Risks associated with commercializing new medical devices.

What Are the Growth Opportunities for NMTC?

• Expanding applications of thin film electrode technology: NeuroOne can leverage its core technology to develop new applications beyond its current focus areas, such as treating other neurological disorders or exploring new therapeutic modalities. The market for neuromodulation therapies is expanding, driven by technological advancements and increasing demand for minimally invasive treatments. This expansion provides NeuroOne with opportunities to diversify its product portfolio and address a wider range of patient needs, potentially leading to increased revenue streams and market share.
• Strategic partnerships and collaborations: NeuroOne can pursue additional partnerships with medical device companies, research institutions, or pharmaceutical companies to accelerate product development, expand its market reach, and access new technologies. Collaborations can provide access to complementary expertise, resources, and distribution channels, enabling NeuroOne to bring its products to market more efficiently and effectively. These partnerships can also enhance the company's credibility and attract further investment.
• Geographic expansion into international markets: NeuroOne can expand its sales and marketing efforts into international markets, particularly in Europe and Asia, where there is a growing demand for advanced neuromodulation therapies. International expansion requires navigating regulatory hurdles and establishing distribution networks, but it can significantly increase NeuroOne's revenue potential and reduce its reliance on the US market. Thorough market research and strategic partnerships are crucial for successful international expansion.
• Development of next-generation electrode technology: NeuroOne can invest in research and development to develop next-generation electrode technology with improved performance, biocompatibility, and functionality. Advancements in materials science and microfabrication techniques can lead to electrodes with enhanced signal quality, reduced invasiveness, and longer lifespan. These improvements can differentiate NeuroOne's products from competitors and attract a larger customer base. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry.
• Securing regulatory approvals for new products: NeuroOne's growth is heavily dependent on obtaining regulatory approvals from the FDA and other regulatory agencies for its sEEG and ablation products. Successful regulatory approvals will allow the company to commercialize its products and generate revenue. Streamlining the regulatory approval process and building strong relationships with regulatory agencies are crucial for accelerating product development and minimizing delays. A clear regulatory strategy and robust clinical data are essential for securing timely approvals.

What Threats Does NMTC Face?

• Competition from larger, established medical device companies.
• Regulatory hurdles and delays in product approvals.
• Technological obsolescence.
• Economic downturns impacting healthcare spending.

What Are NMTC's Competitive Advantages?

• Proprietary thin film electrode technology.
• Strategic partnership with RBC Medical Innovations.
• Focus on specialized applications in neuromodulation.
• Intellectual property protection through patents and trade secrets.

What Does NMTC Do?

NeuroOne Medical Technologies Corporation, founded to address unmet needs in neurological disorder treatment, operates as a medical technology company focused on the development and commercialization of innovative electrode technology. The company's core expertise lies in thin film electrode technology, which is utilized in a range of applications including continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions. These solutions target patients suffering from conditions such as epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. NeuroOne's technology aims to improve the precision and efficacy of neurological interventions. A key strategic partnership with RBC Medical Innovations is focused on developing a radio frequency ablation generator, designed for use with NeuroOne's combination recording and ablation electrode. This collaboration seeks to streamline procedures by enabling simultaneous brain activity recording and tissue ablation using a single electrode. Headquartered in Eden Prairie, Minnesota, NeuroOne is dedicated to advancing the field of neuromodulation through its innovative technology and strategic partnerships.

What Products and Services Does NMTC Offer?

• Develops thin film electrode technology for medical applications.
• Focuses on solutions for continuous electroencephalogram (cEEG) recording.
• Provides technology for stereoelectroencephalography (sEEG) recording.
• Offers solutions for spinal cord stimulation.
• Develops technology for brain stimulation.
• Creates ablation solutions for neurological disorders.

How Does NMTC Make Money?

• Develops and manufactures thin film electrodes.
• Partners with RBC Medical Innovations for radio frequency ablation generator development.
• Seeks regulatory approvals for its medical devices.
• Commercializes its products through direct sales and distribution networks.

What Industry Does NMTC Operate In?

NeuroOne Medical Technologies Corporation operates within the medical device industry, specifically targeting the neuromodulation market. This market is experiencing growth driven by an aging population and increasing prevalence of neurological disorders. The competitive landscape includes larger, established players as well as smaller, innovative companies. NeuroOne's focus on thin film electrode technology and its partnership with RBC Medical Innovations differentiate it from competitors.

Who Are NMTC's Key Customers?

• Hospitals and medical centers.
• Neurosurgeons and neurologists.
• Patients suffering from epilepsy and other neurological disorders.
• Research institutions conducting neurological studies.

Company Profile

NeuroOne Medical Technologies Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Eden Prairie, US. The company is led by CEO David A. Rosa. NMTC has traded publicly since 2018.

NeuroOne Medical Technologies Corporation Financial Trajectory

NeuroOne Medical Technologies Corporation (NMTC) reported $2.0M in revenue for Q3 FY2026, a decline of 17.5% compared to the prior quarter. The company recorded a net loss of $2.0M, with diluted EPS of $-0.23. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, NMTC averaged $-0.22 in diluted EPS.

How NeuroOne Medical Technologies Corporation Is Valued

NeuroOne Medical Technologies Corporation carries a market capitalization of $13.8M, placing it in the micro-cap category. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $1.58, that implies approximately 216% upside potential. Relative to its peer group, NMTC's quantitative score of 21/100 is below the peer average of 52/100.

Return on equity for NeuroOne Medical Technologies Corporation stands at -98.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -84.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -26.3%, the inverse of the P/E and a quick read on earnings relative to price.

NeuroOne Medical Technologies Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.00 places it in the distress zone, a signal of elevated financial risk.

NeuroOne Medical Technologies Corporation has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 23.0% above estimates on average.

Over the past six months, NeuroOne Medical Technologies Corporation insiders filed 18 SEC Form 4 transactions — 5 sales and 13 purchases. On net that is roughly 386K shares acquired (about $290K) — insiders putting money in tends to read as conviction.

NMTC Financials

NMTC Latest News

NMTC Analyst Consensus

NMTC MoonshotScore

NMTC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources